These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35908993)

  • 1. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
    Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
    J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID-19 pandemic lockdowns: A large cohort.
    Barequet D; Shor R; Segal O; Greenbaum E; Trivizki O; Loewenstein A; Rabina G
    Acta Ophthalmol; 2024 May; 102(3):e322-e327. PubMed ID: 37698269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.
    Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö
    Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown.
    Bulut MN; Sönmez HS; Gökçe G; Ağaçkesen A; Bulut K; Hacısalihoğlu A; Arsan A; Şimşek Ş
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102449. PubMed ID: 34314862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
    Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
    BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic.
    Borrelli E; Grosso D; Vella G; Sacconi R; Battista M; Querques L; Zucchiatti I; Prascina F; Bandello F; Querques G
    Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2621-2628. PubMed ID: 33009973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
    Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
    JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Lukacs R; Schneider M; Nagy ZZ; Sandor GL; Kaan K; Asztalos A; Enyedi L; Pek G; Barcsay G; Szabo A; Borbandy A; Kovacs I; Resch MD; Papp A
    BMC Ophthalmol; 2023 Mar; 23(1):110. PubMed ID: 36932356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.
    Sacconi R; Forte P; Tombolini B; Grosso D; Fantaguzzi F; Pina A; Querques L; Bandello F; Querques G
    Ophthalmol Retina; 2022 Jul; 6(7):586-594. PubMed ID: 35227948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
    Chandra S; Arpa C; Menon D; Khalid H; Hamilton R; Nicholson L; Pal B; Fasolo S; Hykin P; Keane PA; Sivaprasad S
    Eye (Lond); 2020 Oct; 34(10):1888-1896. PubMed ID: 31980748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
    Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
    Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
    Hosseini H; Rabina G; Pettenkofer M; Au A; Chehaibou I; Heilweil G; Weiner AJ; Ip M; Loewenstein A; Schwartz SD
    Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1153-1160. PubMed ID: 33245430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between structural and functional treatment outcomes in neovascular age-related macular degeneration.
    Haji H; Gianniou C; Brynskov T; Sørensen TL; Olsen R; Krogh Nielsen M
    Acta Ophthalmol; 2023 Mar; 101(2):177-184. PubMed ID: 36036674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of the French 2020 COVID-19 lockdown on the treatment and follow-up of patients with exudative age-related macular degeneration].
    Auger A; Khanna RK; Bonicel P; Pisella PJ; Le Lez ML
    J Fr Ophtalmol; 2023 Jun; 46(6):596-604. PubMed ID: 37248127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
    Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
    Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
    Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K;
    Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.